Isonarif | 51683-28-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: Isonarif
• 英文别名: [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate;pyridine-4-carbohydrazide
• CAS: 51683-28-4
• 化学式: C49H65N7O13
• 分子量: 960.1
• InChiKey: KGTSLTYUUFWZNW-PPJQWWMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.02
• 重原子数：
  69
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  288
• 氢给体数：
  8
• 氢受体数：
  18

文献信息

• [EN] COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES<br/>[FR] COMPOSITIONS ET PROCÉDÉS COMPRENANT DES ANALOGUES DE LA CAPURAMYCINE
  申请人：SEQUELLA INC

  公开号：WO2009136965A1

  公开（公告）日：2009-11-12

  Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis are provided. In particular, methods and compositions comprising substituted derivatives of capuramycin analogs for the treatment of infectious diseases are provided. Also provided are capuramycin analogue formulations comprising PEGylated compounds, including a PEGylated vitamin E derivative, liposomes and nanoparticle carriers. The invention provides methods and compositions comprising a capuramycin analogue and capuramycin analogues in combination with one or more other active agents.

  提供了治疗由传染性病原体引起的疾病的方法和组合物，特别是结核病。具体而言，提供了包括替代卡普拉霉素类似物的衍生物的方法和组合物，用于治疗传染性疾病。还提供了包括PEG化化合物，包括PEG化维生素E衍生物、脂质体和纳米粒载体的卡普拉霉素类似物配方。本发明提供了包括卡普拉霉素类似物和卡普拉霉素类似物与一个或多个其他活性剂的组合物的方法和组合物。
• ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS
  申请人：PROTOPOPOVA Marina Nikolaevna

  公开号：US20090192173A1

  公开（公告）日：2009-07-30

  Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol.

  本发明提供了用于治疗由传染性病原体引起的疾病，特别是结核病的方法和组合物。具体而言，提供了用于治疗传染病的取代乙二胺的方法和组合物。在一个实施例中，这些方法和组合物用于治疗分枝杆菌感染，包括但不限于结核病。在某些实施例中，本发明包括包含新型取代乙二胺化合物的组合物，进一步包括抗结核药物如利福平、异烟肼、吡嗪酰胺和乙胺丁醇。
• COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES
  申请人：Reddy Venkata

  公开号：US20090281054A1

  公开（公告）日：2009-11-12

  Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis are provided. In particular, methods and compositions comprising substituted derivatives of capuramycin analogs for the treatment of infectious diseases are provided. Also provided are capuramycin analogue formulations comprising PEGylated compounds, including a PEGylated vitamin E derivative, liposomes and nanoparticle carriers. The invention provides methods and compositions comprising a capuramycin analogue and capuramycin analogues in combination with one or more other active agents.

  提供了治疗由感染性病原体引起的疾病的方法和组合物，特别是结核病。具体提供了包含替代的卡普拉霉素类似物衍生物的方法和组合物，用于治疗传染病。还提供了包括PEG化化合物（包括PEG化维生素E衍生物）、脂质体和纳米粒载体的卡普拉霉素类似物制剂。本发明提供了包括卡普拉霉素类似物和卡普拉霉素类似物与一个或多个其他活性剂的组合物和方法。
• Method of treating retained pulmonary secretions
  申请人：MOLICHEM MEDICINES, INC.

  公开号：EP1166794A2

  公开（公告）日：2002-01-02

  A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying it to the respiratory epithelia, such as by generating an aerosol thereof which is then inhaled by the subject. A preferred lantibiotic for carrying out the present invention is duramycin. The method may be used in treating disorders such as cystic fibrosis, chronic bronchitis, and asthma. Also disclosed is a method of combatting tuberculosis comprising administering a lantibiotic to a subject in need of such treatment.

  本发明公开了一种使用兰特生物制剂促进清除受试者肺部残留分泌物的方法。该方法包括向受试者的肺部施用有效量的抗生素。这种抗生素最好是通过局部施用到呼吸道上皮，如产生气溶胶，然后由受试者吸入。用于实施本发明的一种优选兰替比星是杜拉霉素。该方法可用于治疗囊性纤维化、慢性支气管炎和哮喘等疾病。本发明还公开了一种防治结核病的方法，包括向需要治疗的对象施用抗生素。
• 29 human secreted proteins
  申请人：Human Genome Sciences, Inc.

  公开号：US20030220489A1

  公开（公告）日：2003-11-27

  The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

  本发明涉及新型人类分泌蛋白和含有编码这种蛋白的基因编码区的分离核酸。本发明还提供了生产人类分泌蛋白的载体、宿主细胞、抗体和重组方法。本发明还涉及用于诊断和治疗与这些新型人类分泌蛋白有关的疾病、失调和/或病症的诊断和治疗方法。